Compare FTFT & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTFT | TVGN |
|---|---|---|
| Founded | N/A | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 21.3M |
| IPO Year | 2008 | 2021 |
| Metric | FTFT | TVGN |
|---|---|---|
| Price | $3.09 | $6.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.9M | 5.0K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,829,805.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 77.46 | N/A |
| 52 Week Low | $0.55 | $0.14 |
| 52 Week High | $151.68 | $39.00 |
| Indicator | FTFT | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 44.77 |
| Support Level | $3.04 | $6.22 |
| Resistance Level | $3.64 | $7.72 |
| Average True Range (ATR) | 0.50 | 0.56 |
| MACD | -0.14 | -0.05 |
| Stochastic Oscillator | 4.15 | 40.83 |
Future FinTech Group Inc is engaged in the production and sale of fruit juice concentrates (including fruit purees and fruit juices), fruit beverages (including fruit juice beverages and fruit cider beverages) in the PRC. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The Company classified its business segments into Trading Commission and Consulting services, Fast-Moving Consumer Goods (FMCG), and Supply Chain Financing and Trading.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.